BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34400305)

  • 1. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
    Shen N; Yang C; Zhang X; Tang Z; Chen X
    Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy.
    Wang Y; Shen N; Wang Y; Li M; Zhang W; Fan L; Liu L; Tang Z; Chen X
    Biomater Sci; 2021 Apr; 9(8):3019-3027. PubMed ID: 33656040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
    Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
    J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
    Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
    PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
    Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
    J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.
    Pham LM; Poudel K; Ou W; Phung CD; Nguyen HT; Nguyen BL; Karmacharya P; Pandit M; Chang JH; Jeong JH; Ku SK; Yong CS; Choi HG; Kim JO
    Int J Pharm; 2021 Aug; 605():120816. PubMed ID: 34161810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
    Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
    Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
    Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
    Wang X; Li X; Ito A; Sogo Y; Ohno T
    Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
    Ou DL; Lin YY; Hsu CL; Lin YY; Chen CW; Yu JS; Miaw SC; Hsu PN; Cheng AL; Hsu C
    Liver Cancer; 2019 May; 8(3):155-171. PubMed ID: 31192153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
    Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
    Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
    [No Abstract]   [Full Text] [Related]  

  • 20. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.